secwatch.observer — SEC 8-K summary
======================================

Issuer:     Unicycive Therapeutics, Inc. (UNCY)
CIK:        0001766140
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001213900-25-026270
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Unicycive reports FY 2024 net loss of $37.8M; OLC NDA under FDA review with PDUFA June 28, 2025
--------------------------------------------------------------------------------

- Net loss attributable to common stockholders $37.8M or $0.56 per share, vs $31.4M ($1.28) in 2023.
- Cash and cash equivalents $26.1M as of Dec 31, 2024; company expects to fund operations into 2026.
- R&D expenses rose to $20.0M from $12.9M YoY; G&A expenses $12.1M vs $8.5M.
- FDA accepted OLC NDA for hyperphosphatemia; PDUFA target action date June 28, 2025.
- Commercial planning underway for anticipated OLC launch in late 2025 if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1766140/000121390025026270/0001213900-25-026270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1766140/000121390025026270/ea0236324-8k_unicycive.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-026270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer